Chimeric papillomavirus-like particles expressing a foreign epitope on capsid surface loops

Katharina Slupetzky,1 Saeed Shafti-Keramat,1 Petra Lenz,1† Sabine Brandt,2 Andreas Grassauer,2 Margit Sara3 and Reinhard Kirnbauer1

1,2 Laboratory of Viral Oncology, Division of Immunology, Allergy and Infectious Diseases (DIAID)1, and Division of General Dermatology, Department of Dermatology2, University of Vienna Medical School, Währinger Gürtel 18–20, A-1090 Vienna, Austria

3 Center for Ultrastructure Research and Ludwig Boltzmann Institute for Molecular Nanotechnology, University of Agricultural Sciences, Gregor Mendel Strasse 33, A-1180 Vienna, Austria

Neutralization epitope patterns are important determinants for antibody-mediated immune protection against papillomavirus (PV) infection and induced disease. Chimeric L1 major capsid proteins of the human PV type 16 (HPV-16) and the bovine PV type 1 (BPV-1) with a foreign peptide incorporated into several capsid surface loops self-assembled into pentamers or virus-like particles (VLP). Binding patterns of neutralizing monoclonal antibodies (MAb) and immunization of mice confirmed (i) that regions around aa 282–286 and 351–355 contribute to neutralization epitopes and identified the latter region as an immunodominant site and (ii) that placing a foreign peptide in the context of an assembled structure markedly enhanced its immunogenicity. Pentamers disassembled from wild-type HPV-16 and BPV-1 VLPs displayed some of the neutralization epitopes that were detected on fully assembled VLPs, but were deficient for binding a subset of neutralizing MAb that inhibit cell attachment.

Papillomavirus (PV) infections are widespread in animals and humans, causing mostly benign epithelial proliferations, papillomas or warts, of the skin and mucous membranes (Howley, 1991; Lowy et al., 1994; zur Hausen, 1991). Infection with oncogenic types, most often human PV type 16 (HPV-16), has been aetologically associated with the development of anogenital malignancies, in particular cervical cancer (zur Hausen, 1994). PVs are nonenveloped DNA viruses with a icosahedral symmetry and a diameter of approximately 55 nm (Baker et al., 1991). The capsid consists of 60 hexavalent and 12 pentavalent capsomers, with each capsomer being a pentamer composed of 5 L1 major capsid proteins. The second viral structural protein, the minor capsid protein L2, is required for genome encapsidation and the generation of infectious virions (Day et al., 1998; Roden et al., 1996a; Trus et al., 1997). Despite the development of in vitro and in vivo methods, there is still no efficient tissue culture system or laboratory animal to easily propagate HPV, which has hampered immunological and structural studies of the virion (Kreider et al., 1987; Meyers et al., 1997; Roden et al., 1996a).

In recent years progress has been achieved towards development of a prophylactic HPV vaccine to prevent genital HPV infection and associated benign and dysplastic lesions (Kirnbauer, 1996; Schiller & Okun, 1996). Capsid protein(s) L1 alone, or L1 plus L2, expressed in eukaryotic cells self-assembles into virus-like particles (VLP) which are morphologically and antigenically similar to native virions, but lack potentially oncogenic DNA. Immunization with L1 or L1/L2 VLP generated sera containing neutralizing antibodies that conferred type-specific and long-lasting protection in several animal models (Bell et al., 1994; Breitburd et al., 1995; Christensen et al., 1996; Kirnbauer et al., 1992, 1993, 1996; Rose et al., 1998; Suzich et al., 1995). Neutralizing antibodies are thus considered the major protective component in prophylactic PV vaccination.

Because neutralization PV epitopes are non-linear and conformation-dependent, their amino acid composition and surface localization are incompletely characterized. Monoclonal antibody (MAb) binding and immunization studies have tentatively mapped neutralization epitopes of the low-risk HPV-11 along a 20 aa stretch of L1 (residues 120–140), immunodominant sites at aa 131–132 and 346–349 (Ludmerer et al., 1997, 2000), and have implicated L1 residues 50, 266 and 282 in HPV-16 neutralization epitopes (Roden et al., 1997; White et al., 1998). To further explore these epitopes and the potential of VLP as an immunogenic vaccine carrier, we engineered the 8 aa B-cell epitope LELDKWAS (Leu-Glu-Leu-
Asp-Lys-Trp-Ala-Ser) from the human immunodeficiency virus type 1 (HIV-1) gp41 envelope glycoprotein into the L1 protein of HPV-16 and bovine PV type 1 (BPV-1) using inverse touchdown PCR (Ochman et al., 1988). Oligonucleotides encoding the epitope were cloned into several hypervariable regions, encoding the following deduced chimeric L1 epitope sequences:

- A: TANL(ELDKW)ASSN
- B: KKRKL(ELDKWAS)
- C: DATL(ELDKWA)SVHF
- D: KVRK(LELDKWAS)SSNF
- E: RKVT(LELDKWAS)TQT
- F: TPLT(LELDKWAS)SSKF

Fig. 1. Construction of chimeric HPV-16 (A–C) and BPV-1 (D–F) L1–LELDKWAS baculovirus expression vectors. HPV-16 capsid surface loops DE, FG, HI (dotted lines) and amino acid numbering are indicated (Chen et al., 2000). The LELDKWAS peptide (indicated by a bold line) was engineered into the L1 ORF between the indicated amino acid residues, encoding the following deduced chimeric L1 epitope sequences with the added amino acids in brackets:

- A, TANL(ELDKW)ASSN
- B, KGGG(LELDKW)ASSN
- C, KKRKL(ELDKWAS)
- D, DATL(ELDKWA)SVHF
- E, RKVT(LELDKWAS)TQT
- F, TPLT(LELDKWAS)SSKF

(oligonucleotide primer sequences are available on request). Loops and inserts are not drawn to scale. N, C, amino- and carboxy-terminus.

Fig. 1. Construction of chimeric HPV-16 (A–C) and BPV-1 (D–F) L1–LELDKWAS baculovirus expression vectors. HPV-16 capsid surface loops DE, FG, HI (dotted lines) and amino acid numbering are indicated (Chen et al., 2000). The LELDKWAS peptide (indicated by a bold line) was engineered into the L1 ORF between the indicated amino acid residues, encoding the following deduced chimeric L1 epitope sequences with the added amino acids in brackets:

- A, TANL(ELDKW)ASSN
- B, KGGG(LELDKW)ASSN
- C, KKRKL(ELDKWAS)
- D, DATL(ELDKWA)SVHF
- E, RKVT(LELDKWAS)TQT
- F, TPLT(LELDKWAS)SSKF

(oligonucleotide primer sequences are available on request). Loops and inserts are not drawn to scale. N, C, amino- and carboxy-terminus.

For HPV-16 L1, recombinant baculovirus expression vectors were generated with the peptide inserted between amino acid residues 286/287, 281/287 (replacing aa 282–286) or fused to the C terminus as a control (Fig. 1A–C). We also designed BPV-1 L1 chimeras that incorporate the peptide in three different hypervariable regions, between amino acid residues 133/134, 282/286 (replacing aa 283–285) or 351/355 (replacing aa 352–354) (Fig. 1D–F). Recombinant proteins were immunoblotted using MAb Canviv-1 (Pharmingen) and AU-1 (BAbCO), directed against linear proteins were immunoblotted using MAb Camvir-1 (Pharmingen) and AU-1 (BAbCO), directed against linear proteins were immunoblotted using MAb Camvir-1 (Pharmingen) and AU-1 (BAbCO), directed against linear proteins were immunoblotted using MAb Camvir-1 (Pharmingen) and AU-1 (BAbCO), directed against linear proteins were immunoblotted using MAb Camvir-1 (Pharmingen) and AU-1 (BAbCO), directed against linear proteins were immunoblotted using MAb Camvir-1 (Pharmingen) and AU-1 (BAbCO), directed against linear proteins were immunoblotted using MAb Camvir-1 (Pharmingen) and AU-1 (BAbCO), directed against linear proteins were immunoblotted using MAb Camvir-1 (Pharmingen) and AU-1 (BAbCO), directed against linear proteins were immunoblotted using MAb Camvir-1 (Pharmingen) and AU-1 (BAbCO), directed against linear proteins were immunoblotted using MAb Camvir-1 (Pharmingen) and AU-1 (BAbCO), directed against linear proteins were immunoblotted using MAb Camvir-1 (Pharmingen) and AU-1 (BAbCO), directed against linear proteins were immunoblotted using MAb Camvir-1 (Pharmingen) and AU-1 (BAbCO), directed against linear proteins were immunoblotted using MAb Camvir-1 (Pharmingen) and AU-1 (BAbCO), directed against linear proteins were immunoblotted using MAb Camvir-1 (Pharmingen) and AU-1 (BAbCO), directed against linear proteins were immunoblotted using MAb Camvir-1 (Pharmingen) and AU-1 (BAbCO), directed against linear proteins were immunoblotted using MAb Camvir-1 (Pharmingen) and AU-1 (BAbCO), directed against linear proteins were immunoblotted using MAb Camvir-1 (Pharmingen) and AU-1 (BAbCO), directed against linear proteins were immunoblotted using MAb Camvir-1 (Pharmingen) and AU-1 (BAbCO), directed against linear proteins were immunoblotted using MAb Camvir-1 (Pharmingen) and AU-1 (BAbCO), directed against linear proteins were immunoblotted using MAb Camvir-1 (Pharmingen) and AU-1 (BAbCO), directed against linear proteins were immunoblotted using MAb Camvir-1 (Pharmingen) and AU-1 (BAbCO), directed against linear proteins were immunoblotted using MAb Camvir-1 (Pharmingen) and AU-1 (BAbCO), directed against linear proteins were immunoblotted using MAb Camvir-1 (Pharmingen) and AU-1 (BAbCO), directed against linear proteins were immunoblotted using MAb Camvir-1 (Pharmingen) and AU-1 (BAbCO), directed against linear proteins were immunoblotted using MAb Camvir-1 (Pharmingen) and AU-1 (BAbCO), directed against linear proteins were immunoblotted using MAb Camvir-1 (Pharmingen) and AU-1 (BAbCO), directed against linear proteins were immunoblotted using MAb Camvir-1 (Pharmingen) and AU-1 (BAbCO), directed against linear proteins were immunoblotted using MAb Camvir-1 (Pharmingen) and AU-1 (BAbCO), directed against linear proteins were immunoblotted using MAb Camvir-1 (Pharmingen) and AU-1 (BAbCO), directed against linear proteins were immunoblotted using MAb Camvir-1 (Pharmingen) and AU-1 (BAbCO), directed against linear proteins were immunoblotted using MAb Camvir-1 (Pharmingen) and AU-1 (BAbCO), directed against linear proteins were immunoblotted using MAb Camvir-1 (Pharmingen) and AU-1 (BAbCO), directed against linear proteins were immunoblotted using MAb Camvir-1 (Pharmingen) and AU-1 (BAbCO), directed against linear proteins were immunoblotted using MAb Camvir-1 (Pharmingen) and AU-1 (BAbCO), directed against linear proteins were immunoblotted using MAb Camvir-1 (Pharmingen) and AU-1 (BAbCO), directed against linear proteins were immunoblotted using MAb Camvir-1 (Pharmingen) and AU-1 (BAbCO), directed against linear proteins were immunoblotted using MAb Camvir-1 (Pharmingen) and AU-1 (BAbCO), directed against linear proteins were immunoblotted using MAb Camvir-1 (Pharmingen) and AU-1 (BAbCO), directed against linear proteins were immunoblotted using MAb Camvir-1 (Pharmingen) and AU-1 (BAbCO), directed against linear proteins were immunoblotted using MAb Camvir-1 (Pharmingen) and AU-1 (BAbCO), directed against linear proteins were immunoblotted using MAb Camvir-1 (Pharmingen) and AU-1 (BAbCO), directed against linear proteins were immunoblotted using MAb Camvir-1 (Pharmingen) and AU-1 (BAbCO), directed against linear proteins were immunoblotted using MAb Camvir-1 (Pharmingen) and AU-1 (BAbCO), directed against linear proteins were immunoblotted using MAb Camvir-1 (Pharmingen) and AU-1 (BAbCO), directed against linear proteins were immunoblotted using MAb Camvir-1 (Pharmingen) and AU-1 (BAbCO), directed against linear proteins were immunoblotted using MAb Camvir-1 (Pharmingen) and AU-1 (BAbCO), directed against linear proteins were immunoblotted using MAb Camvir-1 (Pharmingen) and AU-1 (BAbCO), directed against linear proteins were immunoblotted using MAb Camvir-1 (Pharmingen) and AU-1 (BAbCO), directed against linear proteins were immunoblotted using MAb Camv...
Chimeric papillomavirus-like particles

Fig. 2. (a) Binding of HPV-16-neutralizing MAb to wt HPV-16 L1 VLP and chimeric HPV-16 L1 proteins A, B, C or disassembled wt capsomers by ELISA. MAbs E70 and V5 inhibit haemagglutination (class A); U4 does not inhibit haemagglutination (class B). (b) Binding of BPV-neutralizing MAb to wt BPV L1 VLP and chimeric BPV-1 L1 proteins D, E, F or disassembled wt capsomers by ELISA. Neutralizing MAbs #6 and #9 inhibit haemagglutination (class A); 5B6 does not inhibit haemagglutination (class B). OD, absorbance at 405 nm.

to wt L1 VLP, the chimeric BPV-1 L1 proteins D 133/134, E 282/286 and wt L1 pentamers was observed. Data for MAb #6 binding to chimera F 351/355 were inconclusive as absorbance values did not decline across 3 logs of antibody dilution. These results indicate that wt pentamers appear sufficient for the display of the #6 epitope and that the determinants were not contained within the targeted L1 regions of chimeras D 133/134 and E 282/286. Antibody #9 (class A) recognized VLP of wt L1 and chimera D 133/134, but no binding was seen with chimeras E 282/286 and F 351/355. This finding raises the possibility that peptide insertion at aa 282/286 and 351/355 had either directly targeted the respective BPV neutralization epitope or indirectly affected the quaternary structure of the particles. In addition, wt pentamers did not react, indicating that MAb #9 requires assembly into VLP for binding. The above findings add to published results indicating that residues 282–286 and 351–355 form part of the neutralization epitopes (Ludmerer et al., 1997, 2000; Roden et al., 1997; White et al., 1998). Reactivity of MAb 5B6 (class B) was specifically absent for construct F 351/355, indicating that peptide targeting to aa 351/355 interrupted the 5B6 epitope. This interpretation is consistent with the observation that aa 346 of the analogous region of HPV-11 L1 is critical for binding of a neutralizing MAb (Ludmerer et al., 1996), although an indirect effect on quaternary structure remains possible. Interestingly, in high resolution reconstructions, MAb 5B6 binds monovalently or divaently to (neighbouring) hexavalent capsomers just above intercapsomer cross-bridges (Trus et al.,
1997). Taken together these data suggest that aa 351–355 contribute to the 5B6 epitope at a virion surface location close to the interpentamer connections. In addition, pentamers appear sufficient for the display of this neutralization epitope. Our results also identify the existence of two sub-classes of neutralizing antibodies within those antibodies that interfere with binding of particles to cell surface (class A). One sub-class (MAb #6) can bind both to intact VLPs and to pentamers/capsomers, while the other sub-class (MAb #9) requires the higher-ordered structure of VLP for binding. The BPV pentamer results are similar to those for the HPV-16 pentamers, which were deficient for E70 binding but bound V5 similarly to intact VLPs.

To examine the effect of peptide insertion on the immunogenicity of BPV-1 L1 proteins, three mice each were injected with native or denatured protein preparations and boosted twice in 2-week intervals. Two weeks after the last immunization, pooled sera were analysed for antibodies against the LELDKWAS peptide and for BPV-neutralizing activity using an *in vitro* focus-forming assay (Dvoretzky *et al*., 1980). Sera raised against native preparations of chimeras D 133/134, E 282/286 and wt VLP neutralized BPV virions with a titre of 1000, 100 and 10000 respectively. This indicated that these chimeric proteins retain PV-neutralization epitopes, although the potency to induce neutralization activity was lower than that of wt VLP. These results suggest the feasibility of inserting epitopes of choice into immunogenic regions of L1, e.g. to generate HPV vaccines with a broad-spectrum protection. In contrast, sera raised against chimera F 351/355 were non-neutralizing, suggesting that peptide insertion at residues 351/355 had disrupted a major immunogenic determinant(s).

To evaluate the potential of assembled chimeric BPV-1 L1 proteins to induce antibodies against the inserted epitope, sera were analysed by ELISA using alkaline phosphatase (AP)–LELDKWAS as the antigen (Fig. 3) (Kerschbaumer *et al*., 1996). Antisera raised against chimera E 282/286 showed insignificant binding to the LELDKWAS peptide, whereas sera raised against chimera F 351/355 showed reactivity comparable to that obtained with MAb 2F5. Thus insertion of a foreign peptide at 351/355 (chimera F) generated a protein that efficiently induced anti-peptide antibodies, while binding of MAb 5B6 and the capacity to induce BPV-neutralizing antisera were completely abrogated. This change of function provides additional evidence that amino acids around 351/355 contribute to an immunodominant neutralization surface structure. Sera raised against chimera D 133/134 also demonstrated significant binding, implicating residues 133/134 as part of another immunogenic region. Remarkably, denatured proteins did not induce immunoreactivity against the peptide, although sera contained antibodies to linear L1 epitopes. This indicated that placing a foreign peptide in the context of an assembled structure markedly enhanced its immunogenicity, whereas the peptide appeared subdominant when presented as denatured (linear) chimeric L1–LELDKWAS protein.

The sera neither reacted to AP–scFv control protein nor neutralized macrophage (BAL) and T-cell tropic (IIIb) HIV-1 laboratory strains by *in vitro* assays, whereas MAb 2F5 directed against this epitope was neutralizing (data not shown). It is likely that in the context of chimeric VLP the epitope did not present in its native conformation as detected on infectious HIV virions. Alternatively, it is possible that the antibody concentration in the sera was too low to score in the assay. This observation represents an important extension to previous results generating autoantibodies against a self-antigen (Chackerian *et al*., 1999), supporting the potential of a virus structure as a vaccine carrier (Zinkernagel & Hengartner, 1997).

Our results corroborate the functional relevance of the crystal structure of an HPV-16 L1 assembled into small *T* = 1 particles (Chen *et al*., 2000), demonstrating that highly variable positions exposed on the pentamer surface can tolerate insertion of heterologous amino acids without losing the salient structural characteristics of L1. By L1 sequence comparison, we had grafted the epitope into three distinct surface loops that connect strands of the β-jelly roll of the L1 monomer, i.e. the DE loop (comprised of HPV-16 aa 111–151), the FG loop (aa 257–298) and the HI loop (aa 349–359) (Fig. 1). Insertion resulted in either a loss or change of function for immunogenic capsid regions (Figs 2 and 3), supporting the role of surface loops as virion neutralization determinants.

The identification of neutralization, immunogenic and mutation-permissive capsid regions may be relevant for HPV vaccine design and allows a rational approach for the insertion of epitopes of choice. The display of foreign peptides in the
context of an immunogenic self-assembled L1 oligomer can induce a vigorous humoral immune response and may thus become a more general procedure to overcome the low immunogenicity of free peptide antigens. This may become an attractive strategy to generate a cross-protective vaccine against multiple HPV types or other, e.g. sexually transmitted, diseases.

We thank Doug Lowy, John Schiller and Thomas Muster for critical reading of the manuscript. This work was supported by grants to R.K. from the Austrian Science Foundation (FWF P13365-MED), the Austrian National Bank (Jubiläumsfonds no. 7688) and the Kommission Onkologie of the University of Vienna Medical School.

References


